Neuroepithelial papillary tumor of the pineal region (PTPR) has been defined as a distinct entity that is increasingly being recognized, with 96 cases now reported. This tumor shares morphologic features with both ependymomas and choroid plexus tumors. PTPR is characterized by an epithelial-like growth pattern in which the vessels are covered by layers of tumor cells forming perivascular pseudorosettes. These tumors exhibit various combinations of papillary and solid architecture, making the differential diagnosis of PTPR difficult to establish. We report the detailed description of the histopathologic features of a large series of PTPRs from 20 different centers and distinguish 2 subgroups of tumors with either a striking papillary growth pattern or a papillary and solid growth pattern. We highlight the findings that PTPRs have unusual vessels with multiple lumina and frequently show detachment of the border of the tumoral cells from the vascular wall. The 2 PTPR subgroups present similar clinical characteristics and immunophenotypes. We confirmed and extended the results of previous ultrastructural studies on the presence of intercellular junctions at the apical part of tumoral cells. The expression of the tight junction proteins claudin-1, claudin-2, and claudin-3 was investigated by immunohistochemistry. Claudin-1 and claudin-3, but not claudin-2, were expressed in PTPRs and in the fetal subcommissural organ, potentially the origin of this tumor. In contrast, all 3 claudins were expressed in choroid plexus papillomas. Claudin expression may help in the diagnosis of PTPRs and can be used in combination with other markers, such as CK18, NCAM, E-cadherin, MAP-2, and Kir 7.1.
21 of which were from French centers. 5, 19, 20, 36, 45 This tumor shares morphologic features with both ependymomas and choroid plexus tumors. PTPRs are characterized by an epithelial-like growth pattern, in which the vessels are covered by layers of tumor cells forming perivascular pseudorosettes. Their immunohistochemical profile is very similar to that of choroid plexus tumors. 20, 36 PTPRs exhibit various combinations of papillary and solid architecture, and their diagnosis remains difficult to establish. Here, we provide the detailed description of their histopathologic features based on a large series of PTPRs from 20 different French centers and describe the ultrastructural characteristics of some of these tumors. Moreover, because well-formed junctional complexes were observed at the apical portions of tumoral cells in PTPRs, 11, 36, 41 we performed an immunohistochemical analysis of the expression of claudins, the most important components of tight junctions, and the results might be useful in the differential diagnosis of PTPR.
MATERIALS AND METHODS

Patients
Samples from PTPRs obtained from 46 patients between 1979 and 2011 were included in this study (Table 1) . They were diagnosed at 20 centers: Angers (Centre Hospitalier Universitaire), Besanc¸on (Centre Hospitalier Universitaire Jean Minjoz), Brest (Centre Hospitalier Universitaire, Hoˆpital Morvan), Bron (Groupement Hospitalier Est, Hoˆpital Neurologique), Caen (Centre Hospitalier Universitaire Coˆte de Nacre), Clermond-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied), Cre´teil (Groupe Hospitalier Henri Mondor), Grenoble (Centre Hopsitalier Universitaire), Lille (Centre Nordpathologie), Limoges (Hoˆpital Dupuytren), Nice (Hoˆpital Pasteur), Marseille (Hoˆpital de la Timone), Orle´ans (Centre Hospitalier Re´gional), Paris (Hoˆpital Lariboisie`re, Centre Hospitalier Saint-Anne and Groupement Hosptilalier Pitie´-Salpeˆtrie`re), Poitiers (Centre Hospitalier Universitaire), Suresnes (Hoˆpital Foch), Toulouse (Centre Hospitalier Universitaire, Rangueil), and Tours (Hoˆpital Bretonneau). Intraoperative touch preparations were performed for all cases at the Groupement Hospitalier Est, Hoˆpital Neurologique, Bron.
All cases were reviewed and diagnosed as PTPR according to histologic criteria described previously. 37 Tumor samples from 4 choroid plexus papillomas and 4 ependymomas were also collected from our center (Centre de Pathologie Est, Bron). The former consisted of 2 typical and 2 atypical subtypes and the latter of 3 grade II ependymomas (1 from the posterior cranial fossa and 2 from the spinal cord) and 1 grade III intracranial ependymoma (fourth ventricle).
Fetal brain material was obtained from 2 spontaneous abortions at 10 and 12 weeks of gestation.
Histology
Biopsies and surgically removed tissues were fixed in 4% paraformaldehyde/15% picric acid, formaldehyde, alcohol-formalin-acetic, or formaldehyde-zinc, embedded in paraffin, and cut into 4-mm sections. Routine staining was performed using hemalun phloxin saffron, hemalun eosin saffron, hemalun eosin, or Mallory phosphotungstic acid, and hematoxylin. Mitoses were counted in 10 randomly selected fields at high magnification ( Â 400) and expressed as the number in 10 high-power fields (HPF = 0.159 mm 2 ). Sections were also stained with periodic acid-Schiff reagent before and after amylase digestion. An automated immunohistochemical analysis of the sections was performed on a BenchMark XT (Ventana Medical Systems Inc, Tucson, AZ) using the antibodies listed below according to the manufacturer's protocol, bound antibodies being detected using avidinbiotin-peroxidase complex and a Ventana kit including DAB reagent. The antibodies used were directed against the following human antigens: pancytokeratins (CKs) recognized by antibody KL1 (clone KL1, 1:50, Beckman Coulter) and antibody AE1/AE3 (clone AE1/AE3, 1:100, Dako), CK18 (clone DC10, 1:50, Dako), CK20 (clone KS 20.8, 1/50, Dako), CK7 (clone OV-TL 12/30, 1/400, Dako), CK5/6 (clone DC5/16B4, 1:50, Dako), neural cell adhesion molecule (NCAM, clone 1B6, 1:125, Novacastra), neuron-specific enolase (NSE, clone H14, 1:500, Dako), synaptophysin (SYN) (clone SP11, prediluted, Ventana), neurofilament (NF, 70 and 200 kDa isoforms, clone 2F11, 1:100, Dako), chromogranin A (ChgA, clone DAK-A3, 1:100, Dako), chromogranin B (ChgB, polyclonal, 1:800, Santa-Cruz), microtubule-associated protein-2 (MAP-2, clone HM2, 1:500, Sigma-Aldrich), vimentin (VIM, V9 clone, 1:300, Dako), glial fibrillary acid protein (GFAP, clone 6F2, 1:200, Dako), S100protein (S100-P) (polyclonal, 1:800, Dako), epithelial membrane antigen (EMA, clone E29, 1:10, Dako), Ecadherin (E-Cad, clone 4A2C7, 1:200, Zymed), transthyretin (TTR, polyclonal, 1:2000, Dako), Bcl-2 (clone 124, 1:50, Dako), Ki67 (clone MIB1, 1 :50, Dako), claudin-1 (CLDN1, Jay.8, 1:100, Zymed Laboratories), claudin-2 (CLDN2, MH44, 1:100, Zymed Laboratories), and claudin-3 (CLDN3, Z23.JM, 1:100, Zymed Laboratories). The number of tumors analyzed using each antibody is shown in Table 2 . Expression of CLDN1 and CLDN2 was analyzed in 17 PTPRs, 12 with papillary (P) and 5 with papillary and solid (PS) patterns, and expression of CLDN3 was analyzed in 14 PTPRs, 12 with P, and 2 with PS patterns. These expressions were compared with the expression in 4 choroid plexus papillomas and 4 ependymomas. Intensity of labeling was scored as 0 when absent, +/ À when weak, or + when strong.
In 33 PTPRs, the Ki67-labeling index was evaluated in the most Ki67-immunoreactive area of the primary tumor. Positive nuclei were counted in about 1000 cells at high magnification (Â 400). Tumoral tissues that had been fixed in Bouin liquor (n = 13) were excluded from this analysis, because of the effect of this fixative on Ki67 antigenicity. The 2 fetal brains were fixed in formaldehyde, embedded in paraffin, and serial coronal and horizontal sections were prepared. The SCO was identified by hemalun phloxin saffron staining.
Electron Microscopy
In 9 PTPRs (cases 2, 4, 5, 7, 16, 30, 31, 33, 34) samples of the tumor were fixed at the time of surgery as described previously, 36 and sections were prepared on an ultramicrotome, stained with uranyl acetate and lead citrate, and examined on a JEOL electron microscope (100 CX 11).
RESULTS
Clinical Data
The main clinical data are summarized in Table 1 . Patients' ages ranged from 5 to 71 years (median age 35 y), with a mean of 36.2 ± 2.7 years (mean ± SEM). The mean age of the male patients (40.4 ± 3.9 y, n = 24) was slightly higher than that of female patients (31.5 ± 3.1 y, n = 22) because of the absence of PTPRs in women older than 60.
Tumor size (maximal diameter, as assessed on preoperative imaging studies or intraoperatively) was 32.0 ± 1.7 mm (mean ± SEM, n = 30; range 20 to 54 mm). Resection of the tumor was achieved in 33 patients, a diagnostic biopsy having been taken in 17. In the remaining 13 cases, surgery consisted only of a diagnostic biopsy (n = 13); 3 were recently diagnosed in the past year, and 1 patient refused further surgery. Detailed follow-up 19 B indicates biopsy; NA, not available; ND, not done; P, papillary; PS, papillary and solid; R, recurrence; S, surgery.
information was available for 31 cases, the mean followup period being 4.5 ± 0.8 years (range 0.1-19 y). Fifteen cases presented a recurrence.
Cytopathology
The touch imprint cytology of the PTPRs showed isolated cells and cell clusters similar to the pattern seen with a neuroendocrine imprint. Cells were small to medium sized, sometimes with a process. The nucleus was eccentric and round to oval, with fine granular or salt and pepper chromatin ( Fig. 1A ).
Histopathology
In 12 cases, the tumors were contiguous with the normal pineal parenchyma ( Fig. 1B) . Thirty of the 46 tumors exhibited a striking papillary (P) growth pattern. The papillae were lined by multilayered cuboidal to columnar tumoral cells arranged in perivascular pseudorosettes (Figs. 1C, D). The other 16 tumors showed both papillary and solid (PS) growth patterns (Figs. 1E, F); sometimes, true rosettes were present ( Fig. 1F ). Of the tumors with only P features, 66.6% had medium-sized cells, 16.6% had small cells, and 16.6% had large cells. In those with PS growth patterns, 50.0% had medium-sized cells, 31.2% had small cells, and 18.8% had large cells. Tumor cell nuclei were eccentrically located within the cytoplasm. The nuclei were sometimes monomorphic, with an oligo-like appearance ( Fig. 1G ), or showed moderate-tosevere pleomorphism ( Fig. 1I ). Anisokaryosis was present in 20.0% of the tumors with P features and in 18.8% of those with PS growth patterns. Three tumors (2 P and 1 PS) had a clear cytoplasm with intracytoplasmic vacuoles (Fig. 1H ).
Abnormal pseudoangiomatous blood vessels with multiple lumina were seen throughout the tumors ( Fig. 2A ). The endothelial cells were not generally hyperplastic and did not show microvascular proliferation.
Detachment of cohesive neoplastic cells forming the perivascular pseudorosettes from the vascular wall was frequently observed (Fig. 2B ). Many of the blood vessels were hyalinized (Figs. 2C, D, E). Pseudoangiomatous and hyalinized vessels could be encountered in the same tumor (Figs. 2D, F).
Mitotic activity was moderate (median: 2 mitosis/ 10 HPF; range, 0 to 20 mitoses/10 HPF), and only 4 PTPRs displayed marked mitotic activity (Z10 mitoses/ 10 HPF). The mean mitotic activity was not statistically different between tumors with a P or PS pattern (2.7 ± 0.7 and 4.6 ± 1.4, respectively). . Intercellular junctions were sometimes identified at the basal pole of tumoral cells facing the vessels (Fig. 3K) . A space was often present between the vascular wall and tumoral cells (Fig. 3L ). Collagen-like material could be observed in perivascular areas ( Fig. 3M ). Tight intercellular junctions were present in many of the endothelial cells.
Electron Microscopy
Immunohistochemistry
The immunohistochemical results are listed in Table 2 . Tumoral cells displayed cytokeratin immunoreactivity in all 38 tumors analyzed. In areas containing papillary structures, pericellular CK18 staining was evident in the cytoplasm of the columnar cells ( Figs. 4A, B ), and apical staining was observed in cells forming a true rosette ( Fig. 4C ). Intense CK18 immunolabeling was also seen in choroid plexus cells adjacent to the PTPR (Fig. 4D ). Immunolabeling with the anti-pancytokeratin antibodies KL1 (Figs. 4E, F) and AE1/AE3 was present in all tumors tested, staining being focal in 4 tumors. No CK20 staining was seen in the 17 tumors tested, whereas only slight CK7 staining was observed in 4 of 18 tumors tested. The neuroepithelial nature of the tumor was shown by NCAM immunoreactivity, which was present in all but one of the 35 tumors analyzed (94%). NCAM staining was strongest on membranes (Figs. 4G, H). No neurofilament protein immunolabeling was seen in the 22 tumors tested, whereas the adjacent pineal parenchyma was intensely stained (Fig. 4I) . The neuroendocrine marker, neuron-specific enolase (NSE), was seen in all 22 tumors analyzed. Focal positivity for synaptophysin was seen in all 44 tumors tested, being more intense in 14% of cases. Chromogranin A (ChgA) was focally expressed in 20% of 40 tumors, being faintly expressed in 7%. One tumor analyzed for chromogranin B presented intense labeling of the perivascular pseudorosettes ( Fig. 4J ). MAP-2 staining was seen in all 6 PTPRs analyzed (Fig. 4K ). Tumoral cells did not express E-cadherin ( Fig. 4L ), whereas choroid plexus cells showed intense staining (Fig. 4M ). Epithelial membrane antigen (EMA) staining was present at different intensities in 19 of 41 tumors analyzed and was restricted to the cell surface, particularly at the pole facing the vessels. All 32 PTRPs tested were vimentin positive, usually with staining of the paranuclear cytoplasm adjacent to vessels walls, and vimentin reactivity was also intense in the vascular walls, highlighting multiple lumina vessels (Figs. 4N,O) . GFAP was observed only in the non-neoplastic pineal gland (Fig. 4P ). Nearly all tumor cells (97% of 36) showed different degrees of S100-P labeling. Bcl-2 was present only in 41% of 22 tumors analyzed. Diffuse cytoplasmic immunoreactivity for transthyretin ( Fig. 4Q ) was observed in 4 of the 5 tumors tested. No clear difference in immunophenotype was observed between P and PS growth pattern tumors. ChgA and Bcl-2 immunolabeling was more frequently observed in tumors with a PS growth pattern (30.0% and 57.2%, respectively) than in those with a P growth pattern (15.0% and 33.3%, respectively).
The Ki67 proliferation index determined in 33 tumors ranged from 1.0 to 29.7% (median, 7.5) with a mean of 8.0 ± 1.3% in tumors with a P growth pattern and 9.1 ± 1.6 in those with a PS pattern, with no statistically significant difference between the 2 subgroups ( Figs. 4S, T) . The pineal gland adjacent to the tumor cells did not show Ki67-positive nuclei (Fig. 4R) . Moreover, only rare positive nuclei were observed in endothelial cells.
Expression of Claudins in the Fetal SCO, Ependyma, and Choroid Plexus
As PTPRs might originate from the SCO, we analyzed the expression of CLDN1, CLDN2, and CLDN3 in the fetal SCO ( Fig. 5A ), fetal ependyma (Fig. 5B) , and fetal choroid plexus (Fig. 5C ). In the 2 fetal brains analyzed, CLDN1 expression was strong in the apical part of the fetal SCO and extended to the processes originating from the floor of the SCO (Fig. 5A1 ). CLDN2 was not expressed in the SCO (Fig. 5A2) . CLDN3 expression was observed in SCO ependymocytes at a low intensity (Fig. 5A3) . In contrast, CLDN1, CLDN2, and CLDN3 were not expressed in the fetal ependyma (Figs. 5B1-B3). Choroid plexuses showed staining for CLDN1 ( Fig. 5C1) , CLDN2 (Fig. 5C2 ), and CLDN3 (Fig. 5C3) at the apicolateral junctions of cells.
Expression of Claudins in PTPRs, Ependymomas, and Choroid Plexus Papillomas
In PTPRs, CLDN1 expression was seen in 76% of the 17 cases tested and was always focal. Immunopositivity was limited to the apicolateral junction of tumoral cells forming large or small tubes ( Fig. 6A) (Fig. 6B) . In solid areas, a cytoplasmic ring-like or dot-like immunoreactivity was sometimes present (Fig. 6C ). CLDN2 was not expressed in any of these 17 PTPR cases (Fig. 6G) , whereas CLDN3 was expressed in 42% of 14 cases with a similar topography to CLDN1 but at a weaker intensity. CLDN1 was expressed in all 4 ependymomas. Immunostaining was located in tubes ( Fig. 6D1) or showed a cytoplasmic ring-like or dot-like pattern (Fig. 6E) . No expression was seen at the vascular pole of perivascular pseudorosettes (Fig. 6D2 ). CLDN2 was not expressed (Fig. 6H) , and weak CLDN3 staining was seen in only 1 case.
In choroid plexus papillomas, CLDN1 (Fig. 6F ), CLDN2 (Fig. 6I) , and CLDN3 were expressed in all cases (4/4). These 3 claudins were expressed at the apicolateral junction of tumoral cells.
The summary of the CLDN1-3 results on PTPRs, ependymomas, choroid plexus papillomas, and fetal tissues is reported in Table 3 .
DISCUSSION
The present study represents the largest series of PTPRs so far reported. The description of several cases of PTPR after our first description in 2003 36 has confirmed PTPR as a separate diagnostic entity. The age of onset of all cases described, including this series, with a range of 15 months to 71 years, a mean of 34.2 ± 1.5 years, and a median of 32 years, shows that this tumor occurs across a wide age range but mostly in young adults. Our series included 10 patients of less than 18 years of age and confirmed that PTPR can occur in children, as reported previously. 35, 48, 51, 55, 75 Combining all previously reported cases and those in our study (total 119 cases), there was no sex difference up to 60 years of age, but no cases were reported in aged women, in contrast to several cases in men older than 60 years (Fig. 7) . The mean follow-up period observed in this series did not differ from the one previously reported. 20 The histopathologic features described in most reports of PTPR include variable proportions of papillary structures interspersed with more diffuse cellular solid areas. 4, 20, 26, 31, 35, 52, 54, 68 As our series was large, it was interesting to review all cases and distinguish tumors with a striking P growth pattern from those presenting a PS growth pattern. The clinical characteristics of the patients and the immunophenotype of the 2 subgroups of tumor were similar. Moreover, common ultrastructural features were found in both groups. The vasculature of PTPRs frequently showed an unusual appearance, with multiple sections of nonhyperplastic vessels forming the core of papillary structures, and clearly differed from glomeruloid angiogenesis, which has been described in highgrade gliomas such as glioblastomas. 14 The mechanism of vascular growth in PTPRs is not known. The absence of CLDN1 CLDN2 CLDN3 marked endothelial hyperplasia and the low proliferation index in vessels suggest that sprouting angiogenesis is not the main mechanism by which the PTPR vasculature grows. One hypothesis is that another type of angiogenesis may be involved, namely intussusceptive angiogenesis, as described in several tumors such as colon and mammary carcinomas 13, 59 and, more recently, in the glioma. 56 This mechanism may partly account for the complex vascular bed observed in PTPRs, because it requires minimal endothelial proliferation. 14 Hyalinization of vessels is similar to that seen in slowly developing tumors, such as myxopapillary ependymomas. 66 The presence of normal pineal parenchyma contiguous with the PTPR, seen in 10 cases, has already been reported. 63 This is in agreement with an origin of this neoplasm from modified cells of the SCO located beneath the pineal gland. 36, 37 Furthermore, the presence of a physiologic increase in nocturnal melatonin levels reported in a patient with PTPR 47 demonstrates that the pineal gland is functioning normally. Characterization of the immunophenotype has made it possible to distinguish PTPRs from other primary or metastatic tumors with papillary features encountered in the pineal region. The most distinctive feature is the strong reactivity for a broad spectrum of CKs, including Cam5.2, AE1/AE3, KL1, and CK18. 4, 20, 41, 43 Intense CK18 expression is a constant finding. 20, 28, 63 In contrast, staining for CK7, CK20, and CK5/6 has been negative in the few cases reported, 46, 61 and our study confirmed the absence of expression of CK7 and CK20 in PTPRs, in contrast to the focal expression of these 2 CKs in choroid plexus tumors 26, 32 with various staining patterns and to their expression in metastatic carcinomas. Moreover, the high expression of NCAM in PTPRs 20,68 is useful in distinguishing these tumors from choroid plexus tumors, which have immunohistochemical similarities with PTPRs but do not show diffuse NCAM immunoreactivity, with NCAM expression being restricted to a few cells. 21 In addition, NCAM immunostaining was shown to be inversely correlated with the histologic grade of malignancy in gliomas, 71 in contrast to the situation in neuroblastomas and some neuroendocrine tumors, in which cancer progression correlates with increased NCAM expression. 44 NCAM expression in PTPRs may be of interest not only for the differential diagnosis of choroid plexus tumors but also to better understand the behavior of this tumor. As serum NCAM has been reported to be a useful marker in patients with glioma, 71 NCAM levels in the serum of patients with PTPR should be investigated. To further confirm the diagnosis of PTPR, the expression of MAP-2 by PTPR tumoral cells may help to distinguish them from choroid plexus tumors. The absence of E-cadherin expression in PTPRs, reported previously 20 and confirmed in our series, is in favor of an ependymal origin of PTPRs, as ependymal cells and ependymomas do not usually express E-cadherin. 21 As reported previously, 20, 36 some PTPRs are positive for the neuronal/neuroendocrine markers synaptophysin and chromogranin A, but staining is only focal. Most PTPRs lack GFAP immunoreactivity and variably display weak membrane or dot-and-ring EMA immunoreactivity. They also tend to express S-100P, transthyretin, and vimentin, the last of which is highly expressed in vessels as previously reported. 11, 20, 36, 37, 68 The results of electron microscopy, performed on a large number of cases in this study, support previous reports regarding the likely secretory nature and ependymal origin of PTPR tumoral cells. 11, 36, 41, 42 The edges of the cells had extensive microvillous processes and prominent elongated intercellular junctions. The presence of microvilli and zipper-like junctions suggests ependymal differentiation. The surface basal lamina was regular and resembled that in the choroid plexus. 22 Our data confirm and extend previous ultrastructural studies with regard to the presence of elongated intercellular junctions.
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The present study is the first to investigate the expression of tight junction proteins in PTPR. Claudins (CLDNs), a superfamily of transmembrane proteins, are essential components of tight junctions in epithelial and endothelial cells. 30, 57 Tight junctions play a crucial role in the maintenance of cell polarity and control of paracellular flux. In the central nervous system, CLDNs are involved in the blood-cerebrospinal fluid barrier; for example, CLDN2 is expressed in choroid plexus epithelial cells. 49 The expression of CLDNs is abnormal in several human cancers, 58 and CLDNs may therefore represent useful diagnostic markers or therapeutic targets. 69 In the field of surgical neuropathology, CLDN1 has shown its utility in the diagnosis of meningiomas 27, 70 and CLDN6 in the diagnosis of atypical teratoid/rhabdoid tumors 3 but with a limited sensitivity and specificity. 2 Our results showed that CLDN expression in PTPRs and ependymomas was similar, with expression of CLDN1 and absence of CLDN2 expression. CLDN2 positivity makes it possible to distinguish choroid plexus papillomas from PTPRs and ependymomas. This is consistent with CLDN2 reactivity in the normal choroid plexus 49 and with its absence in the ependyma and the SCO in our fetal brain controls. The absence of CLDN2 expression may help to discriminate PTPRs from choroid plexus papillomas. Kir 7.1 and stanniocalcin-1 are found in choroid plexus tumors but not in PTPRs. 28 CLDN2 may therefore be a promising marker in the diagnosis of choroid plexus tumors, but this requires further investigation. We hypothesized that PTPRs originate in the SCO, a circumventricular organ of the third ventricle located anteriorly to the pineal gland. 36 The CLDN phenotype of the SCO and PTPRs is similar and may be in favor of this histogenetic hypothesis. Interestingly, CLDN1 analysis of PTPRs frequently reveals a pattern of expression that overlaps the classical EMA topography of tubes and dot/ring-like structures in ependymomas. 29 With regard to CLDN1 expression, there is one main difference between ependymomas and PTPRs. In the PRPRs, CLDN1 expression was frequently observed at the vascular pole of neoplastic cells in perivascular pseudorosettes or papillary structures. This may account for the detachment of neoplastic cells from the vessel wall and the formation of a "clear" space. In contrast, such reactivity was never seen in perivascular pseudorosettes of ependymomas. The downregulation of CLDN expression in cancer may be explained by the loss of differentiation of tumoral cells and may contribute to the motility and invasiveness of neoplastic cells. 53 Intracytoplasmic localization of CLDN1 was observed in less-differentiated areas in several PTPRs (solid sheets). This mislocation of CLDN1 from the cell membrane to the cytoplasm of some tumoral cells, as observed in other tumors, 34 may be explained by an internalization of this tight junction protein and may be involved in tumoral invasiveness by disruption of cell cohesion and loss of cell polarity.
Number of cases
In conclusion, this large series of PTPRs from 20 different French centers has allowed us to report the detailed description of the histopathologic features of PTPR and to show that the P and PS subtypes do not differ in terms of the clinical features of the patients or immunophenotype. We highlight the observations that PTPRs display unusual vessels with multiple lumina and frequently show detachment of tumor cells from the vascular wall. Our data confirm and extend the results of previous ultrastructural studies with regard to the presence of elongated intercellular junctions. The present study is the first to investigate the expression of tight junction proteins in PTPRs and to show that PTPRs express CLDN1 and CLDN3 but not CLDN2. In contrast, all 3 claudins are expressed in choroid plexus papillomas. Claudin expression may help in the diagnosis of PTPR and can be combined with the use of other markers, such as CK18, NCAM, E-cadherin, MAP-2, and Kir 7.1.
